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Abstract 
 
Although ovarian carcinomas with mutated BRCA1 or BRCA2 are sensitive to platinum 
compounds, such carcinomas eventually develop platinum resistance. Previously, we 
showed that acquired resistance to cisplatin in BRCA2-mutated tumors can be mediated 
by secondary intragenic mutations in BRCA2 that restore the wild-type BRCA2 reading 
frame. Here, we show that secondary mutations of BRCA1 also occur in BRCA1-mutated 
ovarian cancer with platinum resistance. We evaluated 9 recurrent BRCA1-mutated 
ovarian cancers previously treated with platinum compounds, including five with 
acquired platinum resistance, one with primary platinum resistance, and three with 
platinum sensitivity. Four of the 6 recurrent platinum-resistant tumors had developed 
secondary genetic changes in BRCA1 that restored the reading frame of the BRCA1 
protein, while none of 3 platinum-sensitive recurrent tumors developed BRCA1 sequence 
alterations. We immunohistochemically confirmed restored expression of BRCA1 protein 
in 2 cases with secondary mutations. Intriguingly, the case with primary platinum 
resistance showed back mutation of BRCA1 in the primary tumor, and showed another 
secondary mutation in the recurrent tumor. Our results suggest that secondary mutations 
in BRCA1 can mediate resistance to platinum in BRCA1-mutated ovarian tumors. 
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Introduction 
 DNA-crosslinking agents such as cisplatin, carboplatin, melphalan and 
cyclophosphamide are widely used anti-cancer drugs. Resistance to these agents is a 
major obstacle to effective cancer therapy. Patients with ovarian cancer usually respond 
well to initial chemotherapy with cisplatin and its derivative carboplatin, but over time 
the majority of patients become refractory to platinum-compounds. Ultimately, 
progression of chemoresistant disease is the major cause of death in women with ovarian 
carcinoma (1).  
      BRCA1 and BRCA2 are tumor suppressor genes responsible for familial 
breast/ovarian cancer. BRCA1 or BRCA2 (BRCA1/2) mutation carriers have increased 
risks of developing breast and ovarian cancer (2). Ten to 15% of all epithelial ovarian 
cancers are associated with inherited mutations in BRCA1/2 (3, 4). The vast majority of 
tumors from women with germline BRCA1/2 mutations demonstrate loss of the wild-type  
BRCA1/2 allele, and are considered to be BRCA1/2 deficient (5-7).   
 BRCA1/2-deficient cancer cells are hypersensitive to DNA-crosslinking agents 
including cisplatin (8-10). Consistently, patients developing BRCA1/2-mutated ovarian 
cancer have a better prognosis compared with non-carriers, if they receive platinum-
based therapy (8, 11). However, even BRCA1/2-mutated ovarian cancers frequently 
develop platinum resistance.  
 Recently, we reported that acquired resistance to cisplatin in BRCA2-mutated 
tumors can be mediated by secondary mutations in BRCA2 that restore the wild-type 
BRCA2 reading frame (12). BRCA2-mutated cancer cells selected in the presence of 
cisplatin acquired secondary genetic changes on the mutated BRCA2 allele, which 
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canceled the frameshift caused by the inherited mutation and restored expression of 
functional nearly-full length BRCA2 protein. Cells with secondary mutations were 
resistant to cisplatin (12).  However, mechanisms of cisplatin-resistance in BRCA1-
mutated ovarian cancer remain unclear. Because both BRCA1 and BRCA2 are involved 
in homologous recombination DNA repair (13, 14) and are required for cellular 
resistance to cisplatin (9, 10), we hypothesized that similar secondary mutations of the 
mutated BRCA1 gene mediate acquired resistance to cisplatin in BRCA1-mutated ovarian 
cancer. Now we report that secondary mutations of BRCA1 also occur in BRCA1-mutated 
ovarian cancer with platinum resistance. 
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Materials and Methods 
 
Clinical specimens. Three DNA samples from recurrent BRCA1-mutated ovarian cancer 
patients were obtained from Cedars-Sinai Medical Center (Los Angeles, CA) through the 
Pacific Ovarian Cancer Research Consortium. Six DNA samples from BRCA1-mutated 
ovarian cancer patients with recurrent disease were obtained from the tissue bank of 
University of Washington (Seattle, WA) (Table 1). DNA from UW80, UW40, UWF27, 
and the recurrent tumor from UW91 were obtained after laser capture microdissection. 
The study was approved by Institutional Review Boards of Fred Hutchinson Cancer 
Research Center and University of Washington. Clinical data of UW40 patient and a 
cancer cell line derived from the same patient’s recurrent tumor (UWB1.289) have been 
reported previously (15). Platinum sensitivity was defined as a complete response to 
treatment maintained without progression for at least six months after platinum therapy. 
Tumors that were resistant or refractory had progressive disease on platinum therapy, less 
than a complete response to platinum therapy or progression within 6 months of 
completing platinum therapy.  
Sequencing of BRCA1. PCR products of genomic DNA were analyzed for sequence 
alterations with BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems; 
Foster City, CA) using ABI 3100 Genetic Analyzer (Applied Biosystems). All detected 
mutations were confirmed by sequencing of an independently amplified template. 
Information of all sequencing and PCR primers for BRCA1 is available in Supplemental 
Table 1. All nucleotide numbers refer to the wild-type cDNA human sequence of BRCA1 
(U14680.1) as reported in the GenBank database.  
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Immunohistochemical studies. BRCA1 protein was detected in formalin fixed paraffin 
sections using the mouse monoclonal antibody MS110 (previously called Ab-1, 
Oncogene Research Products) as previously described (16). The MS110 antibody 
recognizes an amino terminal epitope at BRCA1 (amino acid residues 89-222) (16).  
Briefly, paraffin sections were deparaffinized, washed in PBS and treated with steam heat 
for 20 minutes using antigen target retrieval solution (DAKO). Endogenous peroxidase 
activity in paraffin sections was quenched by treatment with 3% H2O2 for 5 minutes. 
Sections were washed with PBS and non-specific binding was blocked by treatment for 
two hours in 2% bovine serum albumin in PBS. Primary antibody was applied (MS110 at 
1:250 dilution) for 14-16 hours at 4°C.  Secondary antibody and streptavidin biotin-
peroxidase were from the Universal Large Volume LSAB+, Peroxidase kit (DAKO) and 
were each applied for 30 minutes at room temperature. DAB (3,3’diaminobenzidine)-
nickel chromagen (Sigma) was used to visualize antibody complexes and sections were 
counterstained with hematoxylin.  The MS110 antibody can result in non-staining of 
tissues under certain conditions and can be variable in its results. Therefore, we used non-
tumor inflammatory and stromal cells as an internal positive control for BRCA1 protein 
staining for every section.  Decreased protein was only scored if normal cells on the same 
section were positive. Primary and recurrent tumors were stained side by side under 
identical conditions.  MS110 is the most reliable antibody for the immunohistochemical 
detection of BRCA1 (16). Because the MS110 antibody recognizes an amino terminal 
epitope in BRCA1, it cannot distinguish between wild-type BRCA1 protein and truncated 
non-functional protein resulting from frameshift mutations occurring distal to the 
antibody’s epitope. Thus, MS110 is not suitable for distinguishing functional versus non-
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functional BRCA1 protein in UW40, UW208, and UW317. Therefore, we evaluated 
immunohistochemistry in only those tumors with 185delAG mutations (proximal to the 
antibody’s epitope) for which we had paired primary and recurrent paraffin embedded 
tumor samples.   
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Results and Discussion 
 We analyzed 9 clinical samples of recurrent BRCA1-mutated ovarian cancer 
previously treated with platinum (Table 1). Six of them were clinically platinum-resistant 
and 3 were platinum-sensitive. One case (UW40) showed primary resistance to platinum, 
while 5 cases were initially sensitive to platinum and acquired resistance during the 
disease course. Three of the 5 tumors with acquired platinum resistance (UW80, UW91 
and UWF27) and the primarily resistant tumor (UW40) had secondary genetic changes in 
BRCA1, while none of the three cisplatin-sensitive recurrent tumors showed secondary 
genetic changes in BRCA1.  
 UW80 patient is a heterozygous carrier of a frameshift BRCA1 mutation, 
185delAG, which is common in the Ashkenazi Jewish population (17) (Fig. 1A). In the 
primary tumor specimen, only BRCA1 sequence with 185delAG was detected, indicating 
that the tumor had lost the wild-type allele. Loss of heterozygosity (LOH) of an 
intragenic BRCA1 single nucleotide polymorphism (SNP) was also confirmed. In the 
microdissected recurrent tumor from the same patient after development of resistance to 
platinum, LOH of the BRCA1 SNP was confirmed, indicating that the recurrent tumor 
contained only the same single allele of BRCA1 as present in the primary tumor and that 
contamination of non-tumor cells was negligible. In this recurrent sample, wild-type 
BRCA1 sequence represented >80% of the sequences at the mutation site, suggesting that 
the recurrent tumor had acquired wild-type BRCA1 by genetic reversion (back mutation 
to wild-type).  
 Similarly, in 2 more BRCA1.185delAG cases (UW91 and UWF27), the primary 
tumor demonstrated only mutant sequence with loss of the wild-type allele. In the 
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recurrent tumors, we mainly detected wild-type BRCA1 sequence, suggesting that these 
two platinum-resistant tumors acquired wild-type BRCA1 by genetic reversion (back 
mutation to wild-type) (Fig. 1B). Both cases had confirmation of LOH at intragenic SNPs 
in the primary and recurrent tumors (Supplemental Fig. 1), indicating the presence of a 
single BRCA1 allele that underwent a secondary genetic alteration. 
 BRCA1.185delAG encodes a severely truncated protein with 38 amino acids, and 
the back mutation should restore full length BRCA1 protein (Fig. 2A). Consistently, 
immunohistochemical study revealed that BRCA1 protein expression was absent in the 
primary tumors of UW80 and UW91, but strongly positive in their recurrent tumors (Fig. 
2B and data not shown). 
 The mechanism for genetic reversion of 185delAG mutations in all three tumors 
is not clear. At the genomic level, the re-insertion of two missing nucleotides would seem 
less likely to occur than a secondary downstream deletion that corrects the frameshift and 
restores the open reading frame. Several possible explanations for this phenomenon are 
not mutually exclusive. First, we speculate that because 185delAG is in a critical portion 
of the BRCA1 gene close to the RING finger (Fig. 2A), a change of one single amino 
acid here is likely to have deleterious effect on protein function. Similarly, missense 
mutations in the RING finger such as C61G can be deleterious (18). Therefore restoration 
of BRCA1 function may require complete reversion of a mutant in this domain to wild-
type. Another possibility is that the particular genomic sequence surrounding 185delAG 
somehow facilitates the genetic reversion. A third possibility is that other downstream 
mutations do occur in some tumors but are not detected with our relatively short PCR 
amplifications. We are unable to do long range PCR that might identify larger genomic 
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events because of the fragmented nature of our DNA. Thus, it is easier to identify genetic 
reversion in our samples than larger events that restore the open reading frame. 
 UW40 patient is a heterozygous carrier of a frameshift BRCA1 mutation, 
2594delC (Figs. 3A and 3B). The mutant allele encodes an 844 amino acid protein that 
lacks BRCT domains (Fig. 3C). The patient had a past history of breast cancer at the age 
of 42 and developed ovarian cancer at age 54. The primary ovarian carcinoma was 
clinically resistant to platinum. After 6 cycles of platinum and taxol, the patient was 
treated with taxol for 3 additional cycles with development of progression. She was re-
treated with topotecan, then gemcitabine and adriamycin to obtain a partial remission. 
Recurrent tumor was then obtained at the time of surgery for a fistula.  
 LOH of three intragenic BRCA1 SNPs (2201C/T, 2430T/C, and 2731C/T) that 
flank the mutation site was confirmed in both the primary and recurrent tumor (Figs. 3A 
and 3B, and data not shown), indicating that contamination by non-tumor cells was 
negligible and that both the primary and recurrent tumors had lost one BRCA1 allele. 
Intriguingly, in the primary tumor, both wild-type BRCA1 sequence and BRCA1 sequence 
with 2594delC were detected (Figs. 3A and 3B). Careful laser microdissection of a 
separate second sample of this tumor revealed the same result. The presence of both wild-
type BRCA1 sequence and mutant sequence on one allele in the primary tumor suggests 
that genetic reversion (back mutation to wild-type) occurred on one copy of the mutant 
allele. We speculate that the presence of the genetically-reverted wild-type allele in the 
primary tumor contributed to the unusual initial platinum resistance of this tumor.  The 
selective pressure for the genetically reverted tumor cells in the primary ovarian tumor is 
unknown, but may be related to the 11 months of cyclophoshamide, methotrexate and 
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fluorouracil that the patient previously received for breast cancer. Cyclophosphamide is a 
DNA cross-linking agent and could exert similar selection pressure for the correction of 
DNA repair defects as we have observed with exposure to platinum agents.  
An alternative explanation for the existence of genetic reversion and other 
secondary mutations on a mutant allele in this primary tumor is that these events are more 
common than we appreciate but usually occur in only a small number of primary tumor 
cells before exposure to chemotherapy. Then, chemotherapy provides the selection 
pressure for expansion of these sub-clones in recurrent tumors.  Perhaps some reports of 
retention of the wild-type BRCA1/2 allele in breast cancers (19) actually represent genetic 
reversion. Only careful haplotyping distinguishes tumors with retention of the wild-type 
allele from those with genetic reversion.  
 The genetically-reverted wild-type allele was then lost at some point during the 
disease course. In the recurrent tumor, we could no longer detect wild-type sequence, but 
we found a second site small deletion (2606_2628del23) in addition to the inherited 
mutation (2594delC). The second mutation corrects the frameshift caused by the inherited 
mutation and the allele BRCA1.2594delC;2606_2628del23 encodes a BRCA1 protein 
with intact C-terminal region, which may be functional (Fig. 3C). The actual genomic 
DNA sequence of BRCA1 in the UW40 recurrent tumor is a mixture of 
2594delC;2606_2628del23 and 2594delC without a secondary mutation (Fig. 3A).  The 
mixture of sequences on one allele in both the primary and recurrent tumor may have 
occurred by secondary genetic alterations (reversion to wild-type in the primary tumor 
and 23 bp deletion in the recurrent tumor) occurring on just one of the duplicated mutant 
alleles (Fig. 3B), similar to the situation occurring in Capan-1 clones with secondary 
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mutations of BRCA2 observed in the in vitro experiment in the previous report (12). 
Alternatively, the two sequences could represent tumor heterogeneity, with only a subset 
of tumor cells acquiring a secondary mutation on the mutant allele. We favor the 
explanation of tumor heterogeneity in this case, given that a cell line developed from this 
recurrent tumor contains only mutant sequence without secondary genetic changes (15). 
Taken together, secondary mutations that restore the reading frame of mutated 
BRCA1 alleles were frequently observed in ovarian tumors with resistance to platinum. 
These results suggest that secondary mutations of BRCA1 can be a mechanism of 
acquired resistance to cisplatin in BRCA1-mutated ovarian cancer. In addition, the 
observation of the back mutation of BRCA1 in cisplatin-resistant primary tumor of UW40 
patient suggests that secondary mutations of BRCA1 can be a mechanism of primary 
resistance to cisplatin.  
Our studies in this paper and in the previous paper (12) emphasize that BRCA1 
and BRCA2 are not only cancer susceptibility genes, but are also critical determinants of 
clinical sensitivity and resistance to chemotherapy. These studies support the general 
concept that defective DNA repair leads to chemosensitivity, while restoration of 
functional DNA repair contributes to acquired chemoresistance in tumor cells in vitro and 
in vivo.  
Testing for secondary mutations in platinum-treated BRCA1-mutated cancers may 
be clinically important, because tumors with secondary mutations are likely to be 
resistant to platinum and could demonstrate cross-resistance to other agents that exploit 
BRCA1 defects such as poly(ADP-ribose) polymerase 1 inhibitors.  A larger clinical 
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study is warranted to further determine the prevalence and clinical significance of 
secondary mutations of BRCA1 in BRCA1-mutated cancer.  
Our finding could have implications for sporadic ovarian carcinoma. Although 
somatic mutation of BRCA1/2 is rare in sporadic ovarian carcinoma, BRCA1 is  reported 
to be down-regulated in a subset of sporadic ovarian carcinomas by promoter methylation 
and other unknown mechanisms (20). BRCA2 mRNA expression is reported to be 
undetectable by reverse transcription PCR in 13% of ovarian carcinoma (20). Therefore, 
it is tempting to hypothesize that down-regulation of BRCA1/2 causes initial sensitivity 
to cisplatin, and restoration of functional BRCA1/2 expression by demethylation of the 
BRCA1 promoter or other mechanisms leads to acquired resistance. Testing this 
hypothesis will be important to elucidate the more general roles of BRCA1/2 in platinum-
sensitivity and resistance. 
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Table 1. Secondary genetic changes of BRCA1 in BRCA1-mutated ovarian cancer 
treated with platinum.  
          
Patient 
Inherited 
mutation Specimen 
Clinical platinum 
sensitivity 
Secondary genetic 
change 
  Paired specimens   
     
CS1 185delAG pre-platinum sensitive  
  post-platinum sensitive No 
     
CS4 185delAG pre-platinum sensitive  
  post-platinum sensitive No 
     
UW91 185delAG pre-platinum sensitive  
  post-platinum resistant Yes (back mutation) 
     
CS14 185delAG pre-platinum sensitive  
  post-platinum resistant No 
     
UW40 2594delC pre-platinum resistant Yes (back mutation) 
  post-platinum resistant Yes (2606_2628del23) 
     
UW80 185delAG pre-platinum sensitive  
  post-platinum resistant Yes (back mutation) 
     
UWF27 185delAG pre-platinum sensitive  
  post-platinum resistant Yes (back mutation) 
     
  
Non-paired post-treatment 
specimens   
     
UW208 
3867G>T 
(E1250X) post-platinum sensitive No 
     
UW317 3171insTGAGA post-platinum resistant No 
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Figure legends 
Figure 1. Genetic reversion of BRCA1 mutation in 3 recurrent BRCA1-mutated 
ovarian cancer cases.  
A, DNA sequences of BRCA1 in peripheral blood lymphocytes and the primary and 
recurrent tumors from a patient (UW80) with BRCA1-mutated ovarian cancer. In the 
lymphocytes, a heterozygous single nucleotide polymorphism (SNP) of the BRCA1 locus 
(4956A/G) was detected, in addition to a heterozygous mutation (185delAG). In the 
primary tumor, a hemizygous mutation (185delAG) was detected and loss of 
heterozygosity (LOH) of the SNP was confirmed. In the microdissected recurrent tumor, 
LOH of the SNP was confirmed, but wild-type sequence was 80-90% of the sequences 
identified at the site of 185delAG. Importantly, the SNP in the recurrent tumor (4956G) is 
identical to that in the primary tumor (4956G). This indicates that the recurrent tumor had 
acquired wild-type BRCA1 by genetic reversion (back mutation to wild-type). Residual 
wild-type sequence could represent heterogeneity in the tumor. A speculative model of 
BRCA1 alleles in samples from this patient is also depicted. 
B, DNA sequences of BRCA1 in peripheral blood lymphocytes, the primary and recurrent 
tumors from 2 patients (UW91 and UWF27) with BRCA1-mutated ovarian cancer. In the 
lymphocytes, a heterozygous mutation (185delAG) was detected. In the primary tumors, 
a hemizygous mutation (185delAG) was detected. In the microdissected recurrent tumor 
specimens, wild-type sequence was detected, suggesting that the recurrent tumors had 
acquired wild-type BRCA1 by back mutation. Analyses of intragenic SNPs of these cases 
are shown in Supplemental Figure 1. 
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Figure 2. BRCA1 protein expression is restored in recurrent ovarian tumors with 
genetic reversion of BRCA1 mutation. 
A, Schematic presentation of BRCA1 proteins encoded by 185delAG and wild-type 
BRCA1. Functional domains of BRCA1 protein (RING finger, nuclear localization 
signals (NLS) and BRCT domains) are depicted. The region that the BRCA1 antibody 
(MS110) for immunohistochemical staining recognizes (aa 89-222) (16) is also depicted. 
B, Immunohistochemical staining of BRCA1 in a primary tumor with BRCA1.185delAG 
mutation and a recurrent tumor with genetic reversion of the BRCA1 mutation (UW91 
patient). The primary tumors are negative for BRCA1 immunostaining, while the 
recurrent tumors are positive for nuclear BRCA1 immunostaining. Scale bar = 10µm. 
 
Figure 3. Genetic reversion of BRCA1 mutation in a primary ovarian tumor with 
platinum resistance and another secondary BRCA1 mutation in a recurrent tumor 
of the same patient.  
A, DNA sequences of BRCA1 in peripheral blood lymphocytes and the primary and 
recurrent tumors from a patient (UW40) with BRCA1-mutated ovarian cancer. In the 
lymphocytes, heterozygous SNPs of the BRCA1 locus (2201C/T, 2430T/C) were detected, 
in addition to a heterozygous mutation (2549delC). In the primary tumor, LOH of the 
SNPs was confirmed, but the primary tumor specimen shows heterozygous sequence of 
wild-type BRCA1 and a BRCA1 mutation (2594delC). In the recurrent tumor specimen, 
LOH of the SNPs was confirmed and mixed sequences of 2594delC and 
2594delC;2606_2628del23 were detected.  
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B, A speculative model of BRCA1 alleles in samples from this patient. The lymphocytes 
have both the wild-type and mutant (2549delC) alleles. The primary tumor has lost the 
wild-type BRCA1 allele with SNPs 2201T and 2430C, but has retained the allele with the 
inherited mutation (2549delC) and SNPs 2201C and 2430T. This mutant allele has been 
presumably duplicated, and the one of the mutated allele is reverted to wild-type by 
genetic reversion (back mutation to wild-type). In the recurrent tumor, the allele with 
wild-type BRCA1 sequence is lost, and the allele with the inherited mutation (2549delC) 
was again duplicated. One of them obtained a different second mutation 
(2606_2628del23), which cancels the frameshift caused by the inherited mutation 
(2549delC). This model explains why we see mixed sequences of BRCA1 in the primary 
and recurrent tumors. 
C, Schematic presentation of BRCA1 proteins encoded by 2594delC and 
2594delC;2606_2628del23. 
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